Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Stentys looks to prove its latest Apposition IV self-apposing drug-eluting stent by going head-to-head against Medtronic’s Resolute DES in heart attack patients.
Analysts foresee a stable, and possibly improving, road ahead for the U.S. orthopedics market as bellwether Biomet releases preliminary Q2 earnings showing strong growth in knee and hip devices.
The FDA probes Fresenius Medical after more than 900 patients experienced heart attacks at the company’s internal dialysis centers, as detailed in a company memo that wasn’t shared with other Fresenius dialysis device users.